Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618153 | 0.86 | TDP1 (0.54) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL8310679 | 0.83 | RAB9A (0.41) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL10724399 | 0.81 | TDP1 (0.45) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL220318 | 0.79 | VCAM1 (0.47) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL30694393 | 0.79 | VCAM1 (0.47) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL621936 | 0.78 | GPR35 (0.56) | TDP1GPR35ALDH1A1HPGDMAPT | |
| SCHEMBL16959740 | 0.78 | TDP1 (0.45) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL2950121 | 0.78 | VCAM1 (0.50) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL21957846 | 0.78 | VCAM1 (0.50) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL700631 | 0.78 | TSHR (0.58) | TDP1GPR35ALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| CN-116283954-A | Hydroxamate compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-114901656-B | Hydroximic acid ester compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-114901656-A | Hydroximic acid ester compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2022117016-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳微芯生物科技股份有限公司 | 2022-06-09 | — | — | WO | disclosed |
| EP-2668169-B1 | TETRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN INC (US) | 2017-11-15 | — | — | EP | disclosed |
| US-9321740-B2 | Tetrazole compounds and methods of making and using same | ZAFGEN, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20130331420-A1 | TETRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN, INC. (US) | 2013-12-12 | — | — | US | disclosed |
| EP-2668169-A1 | TETRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | Zafgen, Inc. (US) | 2013-12-04 | — | — | EP | disclosed |
| CN-103402989-A | Tetrazole compounds and methods of making and using same | ZAFGEN CORP | 2013-11-20 | — | — | CN | disclosed |
| WO-2012103333-A1 | TETRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ZAFGEN CORPORATION (US) | 2012-08-02 | — | — | WO | disclosed |
| WO-2009087085-A2 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TYK2, WEE2, WEE1 | TDP1 1205/4885GPR35 1916/4885ALDH1A1 3779/4885 |
| US-20130331420-A1 | TETRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | DNPEP, METAP2, TPP2 | TDP1 2083/4885GPR35 1164/4885ALDH1A1 848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.